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Main Text 
 
Continuous-flow left ventricular assist devices (CF-LVAD) are utilised in patients with end-
stage heart failure (ESHF) as a bridge to cardiac transplantation or in some countries, as 
destination therapy (1). Thrombotic and bleeding events are the most frequent and serious 
complications in patients with CF-LVAD (2). As such, warfarinisation and a daily reported 
international normalised ratio (INR) value between 2.0 and 3.0 is required to reduce the 
thrombotic risk (3). The CoaguChek® XS (Roche Diagnostics, Indiana, North America) has 
been approved for use as a form of anticoagulation monitoring. However there is limited data  
in its use for monitoring anticoagulation in patients with a CF-LVAD (4).  
 
We analysed 230 INR values, as measured by CoaguChek® XS and the laboratory (Stago’s 
STA-R Evolution, Leicester, United Kingdom), from 15 patients with CF-LVAD for ESHF 
as a bridge to transplant at The Prince Charles Hospital (Brisbane, Australia) between 
December 2013 and August 2015. Blood samples for each of the testing methods were taken 
on the same day and within a 4-hour window of each other. 
 
Mean age of 40±14 years. 10 (67%) were male and target INR was 2-3 for all patients. 4 
(27%) were on amiodarone, mean creatinine was 89±53 umol/L, mean haematocrit 0.32 (+/-
0.05) and no patients had hepatic synthetic or thyroid dysfunction. There was a moderate 
correlation between laboratory and CoaguChek® XS INR values with a correlation 
coefficient of 0.86 (r2=0.75, p<0.001) shown in Figure 1. Mean INR was significantly 
different between the laboratory and CoaguChek® XS groups (2.55 vs 2.70, mean difference 
0.14; 95% CI: 0.04-0.26, p<0.01). Greater variability was seen with laboratory INR values 
higher than 3.0, with CoaguChek® XS producing higher values (Figure 2).  
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This study supports the use of point-of-care testing with CoaguChek® XS in patients with 
ESHF taking warfarin and who have a Heartware® CF-LVAD. However, CoaguChek® XS 
tended to overestimate the INR in this setting. We advocate point of care CoaguChek® XS 
use in patients who have demonstrated a stable INR within target values on serial laboratory 
measurements. 
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Figure 1 Correlation between INR as measured by CoaguChek® XS and the laboratory 
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Figure 2 Bland-Altman plot comparing INR as measured by CoaguChek® XS and the 
laboratory 
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